Macrophage activation syndrome with acute hepatitis E during tocilizumab treatment for rheumatoid arthritis

2015 ◽  
Vol 82 (4) ◽  
pp. 278-279 ◽  
Author(s):  
Marie Leroy ◽  
Guillaume Coiffier ◽  
Charlotte Pronier ◽  
Louise Triquet ◽  
Aleth Perdriger ◽  
...  
2018 ◽  
Vol 24 (7) ◽  
pp. 413-416
Author(s):  
Ankur Kumar Jindal ◽  
Ashish Agarwal ◽  
Sandesh Guleria ◽  
Deepti Suri ◽  
Mini P. Singh ◽  
...  

2015 ◽  
Vol 2015 ◽  
pp. 1-4 ◽  
Author(s):  
Guido Granata ◽  
Dario Didona ◽  
Giuseppina Stifano ◽  
Aldo Feola ◽  
Massimo Granata

Macrophage activation syndrome (MAS) is a potentially fatal condition. It belongs to the hemophagocytic lymphohistiocytosis group of diseases. In adults, MAS is rarely associated with systemic lupus erythematosus, but it also arises as complication of several systemic autoimmune disorders, like ankylosing spondylitis, rheumatoid arthritis, and adult-onset Still’s disease. Several treatment options for MAS have been reported in the literature, including a therapeutic regimen of etoposide, dexamethasone, and cyclosporine. Here we report a case of 42-year-old woman in whom MAS occurred as onset of systemic lupus erythematosus.


Sign in / Sign up

Export Citation Format

Share Document